Press Releases

SCYNEXIS, Inc. Appoints Steven C. Gilman, Ph.D., to Board of Directors

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2015 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Steven C. Gilman, Ph.D., to its Board of Directors. Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co.

"Dr. Gilman is well-versed in the research and development of novel compounds addressing highly drug resistant and invasive pathogens, and his experience will prove invaluable to us as we continue to develop SCY-078 in this space," said Pamela J. Kirby, Ph.D., Chairman of the Board of SCYNEXIS. "We look forward to having Dr. Gilman on the team as we continue to focus on developing novel anti-infective drugs to treat life-threatening infectious diseases caused by drug resistant pathogens."

Prior to joining Cubist, Dr. Gilman served as Chairman of the Board of Directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager in Inflammation, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College. He currently serves on the board of directors of the Massachusetts Biotechnology Association, Inhibikase, Inc., a privately held biotechnology company, and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.

About SCYNEXIS

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.

Forward Looking Statement

Statements contained in this press release regarding matters that are expected to occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: Media Relations
         Heather Savelle
         MacDougall Biomedical Communications
         Tel: 781-235-3060
         E-mail: hsavelle@macbiocom.com

         Media Relations
         Heather Savelle
         MacDougall Biomedical Communications
         Tel: 781-235-3060
         E-mail: hsavelle@macbiocom.com

         SCYNEXIS, Inc. Contact
         Chuck Osborne
         Chief Financial Officer
         Tel: 919-544-8600
         E-mail: chuck.osborne@scynexis.com

Released February 27, 2015